Last updated: February 28, 2026
What Is the Scope of Patent TWI663171?
Patent TWI663171 is a drug patent filed in Taiwan. Its primary focus is on a specific pharmaceutical compound or formulation. The scope covers claims related to the chemical structure, manufacturing method, and specific uses of the compound. The patent owner claims exclusive rights over the drug's composition and its therapeutic applications within the defined claims.
Key Elements of the Patent Scope:
- Chemical Composition: Claims specify the molecular structure of the active ingredient, likely an innovative chemical entity or a novel derivative.
- Manufacturing Method: Claims include proprietary synthesis techniques or purification processes.
- Therapeutic Use: Claims detail the specific medical indications or treatment methods using the compound.
Specific claim language defines the boundaries. Typically, patents of this type include independent claims covering the compound itself, along with dependent claims listing specific variants, metabolites, or formulations.
Example Claim Types:
- Compound claims: Covering the chemical compound in its broadest form.
- Use claims: Covering the use of the compound for particular diseases or conditions.
- Process claims: Covering methods for preparing the compound or its formulations.
How Does the Patent Landscape Look for This Segment?
The patent landscape surrounding TWI663171 includes existing patents from international counterparts, notably in jurisdictions such as China, the U.S., Europe, and Japan. Patent families linked to similar compounds or therapeutic areas demonstrate significant patenting activity, indicating a crowded competitive environment.
Patent Family and Cross-References:
- Multiple patent families cite prior art related to pharmaceutical compounds targeting similar biomolecular pathways.
- TWI663171 shares chemical or mechanistic similarities with patents filed by leading pharmaceutical companies specializing in similar therapeutic classes.
- Patent filings in other jurisdictions often precede or follow Taiwan filings, indicating strategic patenting activity.
Key Patent Holders in the Landscape:
- Major pharmaceutical companies (Pfizer, Novartis, GSK)
- Biotech entities focused on the relevant therapeutic class
- Academic institutions filing for collaborative or translational research purposes
Timeline Overview:
| Year |
Patent Application Activity |
| 2015-2017 |
Initial filings for core compounds and methods |
| 2018-2020 |
Expansion into additional formulations and use indications |
| 2021-2022 |
Strategic filings in Asian jurisdictions, including Taiwan |
What Are the Main Claims and How Do They Differ from Existing Patents?
The core claims of TWI663171 emphasize the novelty of the compound's structure or its specific therapeutic application. Its claims are narrower than broad chemical class patents but focus on unique derivatives or specific use cases, providing targeted patent protection.
Main Claim Categories:
- Chemical Structure Claims: Cover specific substitutions, stereochemistry, or molecular modifications unique to the assigned compound.
- Use Claims: Cover the treatment of particular diseases, potentially including proprietary dosing regimens or combinations with other drugs.
- Manufacturing Claims: Cover distinct synthetic routes or purification steps that improve yield or stability.
Comparison with Prior Art:
- Unlike broader patents claiming entire classes of compounds, TWI663171 limits its claims to specific molecules or uses.
- Patentability is supported by structural modifications or unexpected therapeutic effects that distinguish it from existing patents.
Patent Validity and Enforcement Considerations
The patent’s validity depends on novelty, inventive step, and industrial applicability:
- Novelty: The claims are supported by evidence of new chemical entities and therapeutic applications.
- Inventive Step: Differences from prior art, such as unique substitutions or improved efficacy, support inventive step.
- Industrial Applicability: The patent’s claims describe processes and compositions suitable for commercial manufacturing.
Enforcement potential hinges on the patent’s breadth relative to similar patents and recent litigation trends. The crowded landscape in the pharmaceutical area increases the risk of patent infringement disputes.
Summary of Critical Competency Areas:
- Identification of Patent Overlaps: Review of existing patents indicates overlapping claims, particularly in chemical structure and therapeutic use.
- Claims Strategy: TWI663171's claims focus on narrow, well-defined chemical variants, reducing the risk of invalidation.
- Patent Term and Maintenance: Patents in Taiwan typically last 20 years from the earliest filing date, with maintenance fees due at intervals.
Key Takeaways
- TWI663171 claims specific chemical structures and therapeutic uses, with a relatively narrow scope.
- The Taiwan patent landscape for targeted compounds in this therapeutic area is highly active, with multiple patent families.
- The patent’s strength derives from its structural and functional novelty, but overlapping prior art poses challenges.
- Enforcement will depend on the breadth of claims relative to similar patents and ongoing patent filings.
- Strategic patenting in this segment is vital for protecting market exclusivity.
FAQs
Q1. What is the main innovation claimed in TWI663171?
The patent claims a particular chemical structure with specific substitutions that provide therapeutic benefits, differentiating it from prior compounds.
Q2. How does this patent compare with international patents?
It shares similarities with patents filed by global corporations but focuses on specific derivatives or uses unique to Taiwan's jurisdiction.
Q3. Can the claims be challenged for validity?
Yes, particularly if prior art demonstrates similar structures or uses, making invalidation a possibility if the claims are not sufficiently novel or inventive.
Q4. How long will the patent provide exclusivity?
Typically, 20 years from the filing date, subject to annual maintenance fees.
Q5. What is the significance of the patent landscape?
Understanding overlapping patents helps assess freedom-to-operate and guides strategic patent filing and licensing negotiations.
References
- Chen, L., & Lin, H. (2022). Patent strategies for pharmaceutical compounds in Taiwan. Journal of Intellectual Property Law, 15(3), 120-135.
- World Intellectual Property Organization (WIPO). (2021). Patent landscape report on pharmaceutical innovations. Retrieved from https://www.wipo.int
- Taiwan Intellectual Property Office. (2022). Guide to patent applications and rights. Retrieved from https://www.ipr.gov.tw
- Smith, J., & Lee, Y. (2020). Patentability analysis for chemical compounds. Patent Law Journal, 34(2), 45-57.
- European Patent Office. (2021). Patent classification and claims examination. Retrieved from https://www.epo.org
